| abstract |
The present invention relates to methods of treating central nervous system disorders, gastrointestinal disorders, overuse of drugs, engine oil, migraine, hypertension and depression, by administering a pharmaceutical composition comprising an effective amount of certain sigma receptor ligands to a patient in need of such treatment. The invention further relates to novel sigma receptor ligands having high binding capacity to the sigma receptor as well as their pharmaceutical compositions. Unexpectedly, certain sigma receptor ligands of the present invention demonstrate selectivity for the sigma receptor to the detriment of the DA, PCP and 5-HT1A receptors. |